This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 777119
In silico trials for drug eluting BVS design,development and evaluation
The aim of InSilc is to develop an in silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive
biological and biomedical knowledge and advanced modelling approaches, to simulate their implantation performance in the individual cardiovascular physiology.
InSilc platform includes multidisciplinary and multiscale models simulating the drug-eluting BVS performance in the acute/short & medium/long term.
MODULES
This poster reflects only the author’s view and the Commission is not responsible for any use that may be made of the information it contains.
+30 265 100 9006 www.insilc.euCoordinator: Prof. Dimitrios I. Fotiadis
Provides a new approach to end users by providing them all stent standard tests in silico.
The purpose of the model is to make an in silico prediction of the effects of the stenting procedure just after the stent deployment.
PLATFORM
3D TAWSS
Follow-up
0 30 60
Max Principal Strain [%]
-10 10 30
Max Principal Stress [MPa]
Lumen Gain: 59%
Malapposi�on: No
Mechanical Modelling Module
DeploymentModule
Fluid DynamicsModule
DegradationModule
Predicts the micro/macro phenomena in blood and in stent restenosis after scaffold implantation.
Myocardium PerfusionModuleProvides predictions of myocardial perfu-sion in the cardiac muscle.
Drug-deliveryModule
1h
6h
3d
7d
28d1d
Includes three-dimensional modelling of drug release employing most novel types of anti-proliferation drugs.
Predicts the degradation and long-term me-chanical performance of the several biore-sorbable material/device systems, through an advanced modelling framework.
InSilcVision
THE MODIFIED 3R
REDUCE
1
2
3
Supplement and accelerate ISO standard
mechanical testing
Reduce the number of subjects involved
in a trial or its duration.
REFINEDecrease the discom-fort for the subjects
the trial involves, while increasing the potential collective
benefits.
REPLACERun entire por-
tions of a clinical trial in silico rather
than in vivo.Supplement clinical studies
with virtual patients
Extrapolate animal testing results to virtual patient vasculature geometries
3D Reconstruction and Plaque Characterization ToolThe 3D Reconstruction and Plaque Characterization Tool is an integrated software tool that can be used to accurately reconstruct a part of the arterial tree including the lumen, the outer wall, as well as the plaques. The tool provides also the ability to accurately reconstruct the post-implantation stent configuration.
Virtual PopulationThe “virtual” population database allows the evaluation of BVS efficacy and safety and the prediction of the interac-tion with the surrounding environment and the scaffold performance through the different virtual scenarios. The virtual database can be found at the website: cardiovascularvirtualpopulation.eu, which is open to researchers.
@InSilc.EUInSilc
Funded bythe European Union
Modules Validation: According to ASME V&V40 - Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices
INSILC CLOUD
InSilcRESTAPI
Statistics
Identify Provider
Experiment Setup Managerand Validator
WorkflowManager
WorkflowRegistry
MODULES
Log and Monitoring
Data Query/Provider
LogDatabase
EntityDatabase
StentRepository
Virtual CaseRepository
ResultRepository
INSILC CLOUD DATABASE STORAGE
INSILC CLOUDFILE STORAGE
Hub
Hub UIApp
AutomatedAgents
File transferManager
INSILCHUB NODE
LocalRepository
INSILCWEB APP
Experiment UI
2D Visualization
3D Visualization
AuthenticationManager
3D Reconstruction and Plaque
Characterization Tool
Local HPC Resources
